文献速递肝病

对肝硬化患者死亡的准确长期预测

Accurate long-term prediction of death for patients with cirrhosis.
PubMed 文献 · Hepatology · 2022-04-01

本研究为回顾性队列研究,利用退伍军人健康管理局30,263例无重大限制生命合并症的肝硬化患者数据训练并内部验证模型,并在OneFlorida临床研究联盟进行外部验证,构建预测肝硬化患者长期生存的风险评分。提升生存树模型判别力最高,1年、3年、5年和10年生存率分别为0.77、0.81、0.84和0.88,外部验证中1年、3年和5年判别力几乎一致。

要点

  • 提升生存树模型预测肝硬化患者长期生存的判别力最高。
  • 模型1年、3年、5年和10年生存率分别为0.77、0.81、0.84和0.88。
  • 外部验证中1年、3年和5年判别力与训练集几乎一致。

核心结论

  • 开发并内部及外部验证了预测肝硬化患者长期生存的风险评分。
  • 该评分将改变肝硬化患者在专科转诊及非肝脏相关治疗决策方面的管理。

研究设计与样本

  • 回顾性队列研究,纳入无重大限制生命合并症的成人肝硬化患者。
  • 使用退伍军人健康管理局的肝硬化成人进行模型训练和内部验证,外部验证使用OneFlorida临床研究联盟。
  • 采用四种模型构建方法,纳入预测肝硬化相关死亡的变量,重点评估1年、3年、5年和10年的判别力。
  • 分析样本为30,263例年龄≤75岁、无重大限制生命合并症且基线期实验室数据完整的肝硬化患者。

主要发现

  • 提升生存树模型判别力最高,1年、3年、5年和10年生存率分别为0.77、0.81、0.84和0.88。
  • 外部验证中1年、3年和5年判别力与训练集几乎一致。
  • 对缺失数据进行插补的二次分析及按肝病病因分组的亚组分析结果与主模型相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cirrhosis is a major cause of death and is associated with extensive health care use. Patients with cirrhosis have complex treatment choices due to risks of morbidity and mortality. To optimally counsel and treat patients with cirrhosis requires tools to predict their longer-term liver-related survival. We sought to develop and validate a risk score to predict longer-term survival of patients with cirrhosis. APPROACH AND RESULTS: We conducted a retrospective cohort study of adults with cirrhosis with no major life-limiting comorbidities. Adults with cirrhosis within the Veterans Health Administration were used for model training and internal validation, and external validation used the OneFlorida Clinical Research Consortium. We used four model-building approaches including variables predictive of cirrhosis-related mortality, focused on discrimination at key time points (1, 3, 5, and 10 years). Among 30,263 patients with cirrhosis ≤75 years old without major life-limiting comorbidities and complete laboratory data during the baseline period, the boosted survival tree models had the highest discrimination, with 1-year, 3-year, 5-year, and 10-year survival rates of 0.77, 0.81, 0.84, and 0.88, respectively. The 1-year, 3-year, and 5-year discrimination was nearly identical in external validation. Secondary analyses with imputation of missing data and subgroups by etiology of liver disease had similar results to the primary model. CONCLUSIONS: We developed and validated (internally and externally) a risk score to predict longer-term survival of patients with cirrhosis. This score would transform management of patients with cirrhosis in terms of referral to specialty care and treatment decision-making for non-liver-related care.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Goldberg D, Mantero A, Kaplan D, et al. Accurate long-term prediction of death for patients with cirrhosis. Hepatology. 2022. PMID: 35278226. doi:10.1002/hep.32457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。